argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
555.70
+3.90 (0.71%)
At close: Mar 28, 2025
51.22%
Market Cap 28.03B
Revenue (ttm) 1.80B
Net Income (ttm) 665.41M
Shares Out n/a
EPS (ttm) 10.21
PE Ratio 42.13
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,307
Average Volume 13,715
Open 552.00
Previous Close 551.80
Day's Range 547.00 - 557.20
52-Week Range 314.70 - 494.00
Beta 0.20
RSI 41.49
Earnings Date Feb 27, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,148
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.